Ribociclib shows promise in indian women with advanced breast cancer

NCT ID NCT07363434

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at how well the drug ribociclib works in real-world settings for Indian women with a common type of advanced breast cancer (HR+, HER2-). Researchers reviewed medical records of 335 patients treated across 18 sites in India. The goal was to measure how long the drug kept the cancer from progressing and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (a targeted cancer drug) plus endocrine therapy
What this could lead to: If successful, this study could confirm that ribociclib works well in Indian patients, supporting its routine use for advanced breast cancer.
What could go wrong: This is a completed real-world study, not a controlled trial, so results may be influenced by patient selection and missing data. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.